Top

Published in:

01-03-2011 | Original Research Article

Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics

A Randomized, Single-Blind, Two-Period Crossover Study in Healthy Subjects

Authors: Dr Ophelia Q.P. Yin, Neil Gallagher, Deirdre Fischer, Lily Zhao, Wei Zhou, Elisabeth Leroy, Georg Golor, Horst Schran

Published in: Clinical Drug Investigation | Issue 3/2011

Abstract

Background and Objective: Nilotinib (Tasigna®), a highly selective and potent BCR-ABL tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukaemia in the chronic phase (CML-CP) and the accelerated phase (CML-AP) in patients resistant or intolerant to prior therapy, including imatinib. Nilotinib has shown competitive inhibition of cytochrome P450 enzyme (CYP) 2C9 in vitro, but its effect on CYP2C9 activity in humans is unknown. This study evaluated the effects of nilotinib on the pharmacokinetics and pharmacodynamics of warfarin, a sensitive CYP2C9 substrate, in healthy subjects.

Methods: Twenty-four subjects (six female, 18 male, aged 21–65 years) were enrolled to receive a single oral dose of warfarin 25 mg with either a single oral dose of nilotinib 800 mg or matching placebo (all administered 30 minutes after consumption of a high-fat meal) in a crossover design. Serial blood samples were collected post-dose for determining serum concentrations of nilotinib and plasma concentrations of S- and R-warfarin. Prothrombin time (PT) and international normalized ratio (INR) values were determined as pharmacodynamic measures of warfarin activity. CYP2C9 genotyping was performed in all subjects using TaqMan® assay.

Results: Sixteen subjects were identified as CYP2C9 extensive metabolizers (EMs) and eight as intermediate metabolizers (IMs). There were no CYP2C9 poor metabolizers. Pharmacokinetic parameters of S- and R-warfarin were similar between the two treatments (warfarin + nilotinib vs warfarin alone) in both the EM and the IM groups. The geometric mean ratios (90% CIs) for the maximum concentration in plasma (C_max) and area under the concentration-time curve from time zero to infinity (AUC_∞) of S-warfarin in plasma in all subjects were 0.98 (0.95, 1.02) and 1.03 (0.99, 1.07), respectively, and for R-warfarin 1.00 (0.96, 1.04) and 1.02 (0.99, 1.04), respectively. Mean ratios for the maximum observed value and AUC from time zero to the last sampling time for PT were 1.00(0.96,1.04) and 1.00(0.98,1.02), respectively, and for the maximum observed value for INR and the AUC from time zero to the last sampling time for INR were 1.00(0.97,1.03) and 1.00(0.99, 1.01), respectively. Mean ± SD serum nilotinib C_max was 1872 ±560 ng/mL, which is comparable to steady-state C_max in CML and gastrointestinal stromal tumour patients receiving twice-daily 400 mg doses. Adverse events observed following either treatment were generally consistent with the known safety profiles of both drugs, and no new safety issues were observed.

Conclusion: The study results demonstrate that nilotinib has no effect on single-dose warfarin pharmacokinetics and pharmacodynamics. This implies that nilotinib is unlikely to inhibit CYP2C9 activity in human subjects. These findings suggest that warfarin and nilotinib may be used concurrently as needed.

Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib) a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94: 1765–9PubMedCrossRef

Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 BCR-ABL activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005; 104: 1230–6PubMedCrossRef

Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, had in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005; 11: 4941–7PubMedCrossRef

Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129–41PubMedCrossRef

Nilotinib (Tasigna®) [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2007 Oct

Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–51PubMedCrossRef

Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443–69PubMed

U.S. Food and Drug Administration (FDA). Guidance for industry: drug interaction studies — study design, data analysis, and implications for dosing and labeling. Rock-ville (MD): FDA 2006

Breckenridge A, Orme M, Wesseling H, et al. Pharmaco-kinetics and pharmacodynamics of the enantiomers of warfarin in men. Clin Pharmacol Ther 1974; 15: 424–30PubMed

10.

Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67–74PubMedCrossRef

11.

Tamazaki H, Shimada T. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S- warfarin enantiomers. Biochem Pharmacol 1997; 54:1195–203CrossRef

12.

Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics 2003; 3: 202–14CrossRef

13.

Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717–9PubMedCrossRef

14.

Kumar V, Brundage RC, Oetting WS, et al. Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 2008; 36: 1242–8PubMedCrossRef

15.

U.S. Food and Drug Administration (FDA). Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Rockville (MD): FDA 2002

16.

Benet L. Relevance of pharmacokinetics in narrow therapeutic index drugs. Transplant Proc 1999; 31: 1642–4PubMedCrossRef

17.

He YL, Sabo R, Riviere GJ, et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007; 5: 1131–8CrossRef

18.

Common Toxicity Criteria for Adverse Events v 3.0 (CTCAE) [online]. Available from URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. [Accessed 2010 Nov 19]

19.

Obach RS, Walsky RL, Venkatakrishnan K, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316: 336–48PubMedCrossRef

20.

Yacobi A, Levy G. Protein binding of warfarin enantiomers in serum of humans and rats. J Pharmacokinet Biopharm 1977; 5: 123–31PubMedCrossRef

21.

Bjornsson TD, Meffin PJ, Swezey S, et al. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. J Pharmacol Exp Ther 1979; 210: 316–21PubMed

22.

Diana FJ, Veronich K, Kapoor AL. Binding of nonsteroidal anti-inflammatory agents and their effect on binding of racemic warfarin and its enantiomers to human serum albumin. J Pharm Sci 1989; 78: 195–9PubMedCrossRef

23.

Serlin MJ, Mossman S, Sibeon RG, et al. Interaction between diflunisal and warfarin. Clin Pharmacol Ther 1980; 28: 493–8PubMedCrossRef

24.

Sands CD, Chan ES, Welty TE. Revisiting the significance of warfarin protein-binding displacement interactions. Ann Pharmacother 2002 Oct; 36: 1642–4PubMedCrossRef

25.

Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71:115–21PubMedCrossRef

26.

Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. New York: Lippincott Williams & Wilkins, 1995

Title: Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics
A Randomized, Single-Blind, Two-Period Crossover Study in Healthy Subjects
Authors: Dr Ophelia Q.P. Yin
Neil Gallagher
Deirdre Fischer
Lily Zhao
Wei Zhou
Elisabeth Leroy
Georg Golor
Horst Schran
Publication date: 01-03-2011
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 3/2011
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.2165/11538700-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics

A Randomized, Single-Blind, Two-Period Crossover Study in Healthy Subjects

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Effects of Manidipine and its Combination with an ACE Inhibitor on Insulin Sensitivity and Metabolic, Inflammatory and Prothrombotic Markers in Hypertensive Patients with Metabolic Syndrome

Importance of C-Reactive Protein Level in Predicting Non-Response to Additional Intravenous Immunoglobulin Treatment in Children with Kawasaki Disease

Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers

Effect of Inhibition of Cytochrome P450 Enzymes 2D6 and 3A4 on the Pharmacokinetics of Intravenous Oxycodone

Effects of Structured Follow-Up and of More Effective Acid Inhibitory Treatment in the Management of GORD Patients in a Swedish Primary-Care Setting